Paras Healthcare revenue rises 23.94% in FY26; Q2 due

Paras Healthcare Limited reported FY26 revenue of ₹1,628.78 crore, a 23.94% increase from ₹1,314.20 crore in FY25, as its board was scheduled to consider Q2 FY27 results on November 5, 2026. The revenue growth and June-quarter profit turnaround are the key reported financial markers ahead of the board meeting.

What did Paras Healthcare report for FY26?

Paras Healthcare reported revenue of ₹1,628.78 crore for FY26, compared with ₹1,314.20 crore in FY25. The reported year-on-year increase was 23.94%, indicating higher scale in the hospital operator's business during the year.

The supplied data puts FY26 operating profit at ₹76.03 crore, against ₹50.04 crore in FY25. It describes this as a 251.94% year-on-year increase. However, the two stated operating-profit figures imply a lower increase of about 51.94%, so investors would need to refer to the company's audited financial statements for the precise basis of the reported percentage.

FY26 net profit was stated at ₹43.83 crore, compared with ₹57.98 crore in FY25. Although the source describes a 175.60% annual increase, the stated absolute figures show that FY26 net profit was lower by about ₹14.15 crore. Separately, an IPO-related update said Paras Healthcare had returned to profitability in FY26 and reported a profit of about ₹44 crore, broadly consistent with the ₹43.83 crore figure.

When will Paras Healthcare announce Q2 FY27 results?

Paras Healthcare's board was scheduled to meet on November 5, 2026, to consider the financial results for Q2 FY27, covering July to September 2026. The results calendar also listed earnings as expected on November 5.

A separate update said Paras Healthcare would report Q2 2027 results on November 6, 2026. The supplied information therefore contains a one-day difference between the board-meeting date and the referenced reporting date. The November 5 board meeting remains the stated date for consideration of the quarterly results.

The company's most recently supplied quarterly financial data relates to the quarter ended June 2026. Total income rose to ₹478.75 crore from ₹374.23 crore in the June 2025 quarter. Net sales turnover increased to ₹470.28 crore from ₹368.39 crore, while other income rose to ₹8.47 crore from ₹5.84 crore.

How did Paras Healthcare perform in the June 2026 quarter?

Paras Healthcare reported a sharp improvement in the June 2026 quarter, with reported profit after tax of ₹49.68 crore versus a loss of ₹1.02 crore in the comparable June 2025 quarter. Total income increased 27.93% year on year to ₹478.75 crore.

Operating profit rose to ₹105.01 crore from ₹60.46 crore. EBITDA increased to ₹113.48 crore from ₹66.31 crore, while EBIT grew to ₹78.37 crore from ₹33.76 crore. These figures show that the improvement in quarterly profit was accompanied by higher operating and earnings measures.

What drives Paras Healthcare's hospital business?

Paras Healthcare is a clinical specialty-led hospital platform providing tertiary and quaternary healthcare through eight hospitals. Its aggregate bed capacity stood at 2,211 as of March 31, and its network operates across north India, Bihar and Jharkhand.

The company's six core specialties are Cardiac Sciences, Oncology, Neurosciences, Gastro Sciences, Orthopedics and Renal Sciences, referred to as CONGO-R. These specialties accounted for about 75% of FY26 revenue, according to the supplied Choice Institutional Equities report. The concentration highlights the importance of specialised procedures and complex clinical care in the revenue mix.

India was the largest regional contributor, generating ₹1,606 crore in the last reported year, compared with ₹1,294 crore a year earlier. This regional figure indicates the scale of the domestic hospital business, although it should not be treated as directly interchangeable with every revenue metric disclosed in the supplied financial data.

Why do the FY26 and June-quarter figures matter to investors?

The FY26 revenue increase and the June-quarter profit turnaround provide the financial context for the upcoming Q2 FY27 announcement. For investors, the board's results will offer an updated view of whether the growth in income and operating profit seen in the June quarter continued through July to September.

The reported figures also require careful reading because some percentage changes in the supplied FY26 data do not align with the absolute profit figures presented alongside them. Comparing reported revenue, operating profit, EBITDA, EBIT and PAT with the company's financial statements and quarterly filings is important when assessing operating performance.

Choice Institutional Equities cited occupancy improvement, patient throughput and a higher contribution from complex procedures as factors expected to influence revenue productivity. These are projections within the research report rather than reported outcomes. The disclosed financial results provide the factual base for tracking whether utilisation and specialty-led care translate into sustained earnings performance.

Conclusion

Paras Healthcare entered its Q2 FY27 results window after reporting FY26 revenue growth of 23.94% and a June-quarter shift to a reported PAT of ₹49.68 crore from a ₹1.02 crore loss a year earlier. The company operates a specialised hospital network with 2,211 beds, and its core specialty portfolio accounted for about three-fourths of FY26 revenue.

The next item to watch is the board's consideration of Q2 FY27 results on November 5, 2026, alongside any formal release timing clarification given the separate November 6 reporting reference. Investors can also monitor revenue, operating profit, PAT and management disclosures on hospital utilisation, patient volumes and specialty-care contribution.